GLP-1 Agonist
6 compounds in this category.
Semaglutide
FDA ApprovedOzempic, Wegovy
A GLP-1 receptor agonist originally developed for type 2 diabetes, now widely prescribed for weight management. One of t…
Route
SubQ (Ozempic/Wegovy)
Dose
0.25 mg → 2.4 mg (titrated over 16–20 weeks)
Cycle
Ongoing — not typically cycled
Orforglipron
InvestigationalLY3502970, Eli Lilly oral GLP-1
A non-peptide, small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike semaglutide and tirzepatide which ar…
Route
Oral tablet (investigational)
Dose
12–45 mg (dose range studied in trials)
Cycle
Ongoing — not commercially available
Liraglutide
FDA ApprovedVictoza, Saxenda
The first widely used GLP-1 receptor agonist for weight management, developed by Novo Nordisk. Predates semaglutide and …
Route
SubQ (Saxenda/Victoza)
Dose
0.6 mg → 3.0 mg (titrated over 5 weeks)
Cycle
Ongoing — not typically cycled
Lixisenatide
FDA ApprovedAdlyxin, Lyxumia
A once-daily GLP-1 receptor agonist FDA-approved for type 2 diabetes. Shorter-acting than semaglutide, with a stronger e…
Route
SubQ
Dose
10 mcg for 14 days, then 20 mcg
Cycle
Ongoing
Exenatide
FDA ApprovedByetta, Bydureon
The first GLP-1 receptor agonist approved by the FDA, originally derived from Gila monster saliva. Available in twice-da…
Route
SubQ
Dose
5–10 mcg (Byetta) or 2 mg (Bydureon)
Cycle
Ongoing
Dulaglutide
FDA ApprovedTrulicity
A once-weekly GLP-1 receptor agonist FDA-approved for type 2 diabetes and cardiovascular risk reduction. Developed by El…
Route
SubQ
Dose
0.75 mg → 4.5 mg (titrated)
Cycle
Ongoing